Argenx Sinks 11% as Sjogren’s Trial Halted for Futility: “Disappointed by This Outcome”
Argenx (ARGX) shares dropped 11% after halting a Phase 3 trial of Vyvgart Hytrulo for Sjogren's disease due to futility. The company expects revenue to grow from $4.25B in 2025 to $9.33B in 2028, trading at about 24x forward earnings. Other trials, including a Phase 3 myositis win and Phase 2 celiac results, continue.
How this was made
The 30-second read
Why it matters
The futility decision removes a future revenue source, reinforcing a bearish outlook for the stock in the near term.
Market read
The news directly caused an 11% intraday drop, indicating immediate market relevance for traders.
What to watch
Argenx's myositis Phase 3 success and upcoming Phase 3 for FB102 could offset the setback, and the trial readout was not due until 2027.
Background
Argenx (ARGX) is a biotech focused on autoimmune diseases; Vyvgart is its flagship antibody therapy.
Ticker impact
Shares dropped 11% after Argenx halted its Phase 3 UNITY trial for Vyvgart in Sjogren's disease due to futility.
downward pressure as investors price in the lost indication
A Phase 3 failure is material for a biotech; the market already reacted with an 11% sell‑off and may continue to sell on the news.
Market effects
Biotech sector may see broader risk‑off pressure on companies with late‑stage autoimmune programs.
European and US biotech markets could experience modest declines.
Limited to biotech investors; no broad macro impact.
Counterpoint
The trial halt may be over‑reacted to; the drug still has potential in other indications and the company retains strong pipeline momentum.
Key entities
- CompanyArgenx
Biopharma developing Vyvgart and other autoimmune therapies.
- ExecutiveLuc Truyen
Chief Medical Officer of Argenx who announced the trial halt.
